Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling by van Dinther, Maarten et al.
Anti-Sclerostin Antibody Inhibits Internalization of
Sclerostin and Sclerostin-Mediated Antagonism of Wnt/
LRP6 Signaling
Maarten van Dinther1, Juan Zhang1, Stella E. Weidauer2, Verena Boschert2, Eva-Maria Muth2,
Achim Knappik3, David J. J. de Gorter1, Puck B. van Kasteren1¤, Christian Frisch3, Thomas D. Mueller2,
Peter ten Dijke1*
1Department of Molecular Cell Biology and Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands, 2Department of Molecular Plant
Physiology and Biophysics, Julius-von-Sachs Institut, Wuerzburg, Germany, 3AbD Serotec, a Bio-Rad company, Puchheim, Germany
Abstract
Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product,
Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of
osteoporosis. The exact molecular mechanism by which Sclerostin exerts its antagonistic effects on Wnt signaling in bone
forming osteoblasts remains unclear. Here we show that Wnt3a-induced transcriptional responses and induction of alkaline
phosphatase activity, an early marker of osteoblast differentiation, require the Wnt co-receptors LRP5 and LRP6. Unlike
Dickkopf1 (DKK1), Sclerostin does not inhibit Wnt-3a-induced phosphorylation of LRP5 at serine 1503 or LRP6 at serine 1490.
Affinity labeling of cell surface proteins with [125I]Sclerostin identified LRP6 as the main specific Sclerostin receptor in
multiple mesenchymal cell lines. When cells were challenged with Sclerostin fused to recombinant green fluorescent
protein (GFP) this was internalized, likely via a Clathrin-dependent process, and subsequently degraded in a temperature
and proteasome-dependent manner. Ectopic expression of LRP6 greatly enhanced binding and cellular uptake of Sclerostin-
GFP, which was reduced by the addition of an excess of non-GFP-fused Sclerostin. Finally, an anti-Sclerostin antibody
inhibited the internalization of Sclerostin-GFP and binding of Sclerostin to LRP6. Moreover, this antibody attenuated the
antagonistic activity of Sclerostin on canonical Wnt-induced responses.
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Introduction
The mass, biomechanical properties and structural integrity of
bone is kept in balance by continuous cycles of bone resorption
and bone formation [1,2]. In osteoporosis, the balance between
bone degradation and formation is perturbed: more bone is
broken down than is formed [3]. Osteoporosis has a high
incidence and patients can, amongst others, be treated with
bisphosphonates, selective estrogen modulators and inhibitors of
RANKL [4], all of which can effectively prevent further bone loss.
However, since osteoporosis is often diagnosed at a stage when
extensive bone loss has already occurred, there is a dire need for
novel therapies that stimulate new bone formation to restore bone
integrity [5]. Whereas osteoporosis is defined by an overall bone
loss, on the other side of the spectrum are rare diseases that are
characterized by excessive bone formation [6,7]. In contrast to the
multi-factorial osteoporosis, the high bone mass disorders are often
monogenic. The genes that are linked to these disorders are
considered to be potential therapeutic targets for the treatment of
osteoporosis [8].
One example of a high bone mass disease is Sclerosteosis, which
affects a number of families in South Africa [9,10]. This disease
has been linked to mutations in the SOST gene that lead to
inactivation of its product Sclerostin [11,12]. The absence of this
protein leads to dramatic bone overgrowth in mice and over-
activity of canonical Wnt signaling in bone tissue [13,14].
Sclerostin is expressed and subsequently secreted by osteocytes
[10,15] and interacts with the Wnt co-receptors low density
lipoprotein receptor-related protein (LRP) 5 and 6 [16–18]. These
are single transmembrane proteins that share 73% sequence
identity and are essential for canonical Wnt signaling [19,20]. Both
contain in their extracellular domain four six-bladed b-propeller
structures with so-called YWTD repeats. The four propellers share
only 19% sequence similarity among each other and have different
functional properties. Sclerostin was shown to interact with the
first, most amino-terminal propellers of both LRP5 and 6 [21].
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Interestingly, gain of function mutations in LRP5 result in high
bone mass [22,23]. These gain of function LRP5 mutants show
reduced Sclerostin binding [24]. Sclerostin has recently been
shown to also interact with LRP4 and certain mutations in this
receptor were found to decrease the interaction with Sclerostin
[25].
Canonical Wnt signaling is initiated by direct binding and
heteromeric complex formation of seven-transmembrane receptor
Frizzled proteins and the LRP5 and 6 co-receptors upon
interaction with specific Wnt ligands, which leads to the
stabilization of cytoplasmic b-Catenin [26]. In the absence of
Wnt ligands, b-Catenin forms a complex that includes Adenoma-
tous polyposis coli (APC), Axin and Glycogen synthase kinase 3
(GSK3). This complex facilitates phosphorylation and subsequent
proteasomal degradation of b-Catenin. In the presence of Wnt
ligands, this complex dissociates, and b-Catenin accumulates and
translocates to the nucleus, where it interacts with TCF/Lef1
transcription factors and initiates transcription of specific target
genes, such as Axin [26,27].
Like Sclerostin, Dickkopf 1 (DKK1) glycoproteins inhibit
canonical Wnt signaling by binding to LRP5 and 6 [28]. DKK1
mainly interacts with the third and fourth propeller of these
proteins [29], but can also bind to the first and second propellers
[29,30]. At least two mechanisms have been proposed by which
DKK1 exerts its antagonistic effects on LRP5 and 6: DKK1
mediates the recruitment of co-receptor Kremen to LRP5 and 6,
thereby inducing endocytosis of LRP5 and 6 [28,31] and/or
DKK1 disrupts the formation of the Wnt-induced Frizzled-LRP6
complex [32].
Here we describe the genetic and biochemical interaction of
Sclerostin with the Wnt co-receptors LRP5 and LRP6. In
addition, we show that GFP-tagged Sclerostin is internalized,
most likely via a Clathrin dependent pathway, and is subsequently
degraded in a proteasome-dependent manner. Moreover, we
describe antibodies that specifically interfere with binding of
Sclerostin to Wnt co-receptors and stimulate osteoblast differen-
tiation. Such neutralizing Sclerostin antibodies may be used for
future anabolic treatment of osteoporosis.
Results
Wnt/b-catenin-induced Responses Depend on LRP5 and
LRP6
To investigate the role of LRP5 and LRP6 in Wnt-induced
responses, Wnt3a-conditioned media was used to stimulate the
mouse myoblast cell line C2C12 cells, which were depleted for
either LRP5 or LRP6 by lentiviral shRNA mediated knockdown.
C2C12 cells transduced with a non-targeting shRNA construct
served as a control. Knockdown efficiency was determined by
quantitative real-time PCR (qRT-PCR) and both LRP5 and
LRP6 were efficiently and specifically targeted by their specific
shRNAs. Knockdown of LRP6 induced some up-regulation of
LRP5 mRNA expression. (Fig. 1a). Knockdown of LRP5 or LRP6
was equally efficient in inhibiting the Wnt3a-conditioned media
induced canonical signaling as measured by b-Catenin/TCF-
dependent BAT-luc transcriptional luciferase reporter activity
(Fig. 1b) and induction of mRNA expression of AXIN2, a direct
Wnt target gene (Fig. 1c). Apparently, the LRP6 up-regulation in
LRP5 knockdown cells was insufficient to obtain a rescue of the
response. When Wnt3a conditioned media was replaced with
recombinant Wnt3a similar results were obtained (Fig. S1a). Thus
both co-receptors are critically important in the Wnt/b-catenin
responses in C2C12 cells. Similar results were obtained when cells
of the osteoprogentior cell line KS483 were depleted of LRP5 or
Figure 1. Small hairpin RNA (shRNA) mediated knockdown of
LRP5 and LRP6 inhibits Wnt3a-induced responses. (A) qRT-PCR
was performed on cDNA obtained from C2C12 cells with stable
knockdown of LRP5 and LRP6 to determine the efficiency of the
knockdown. (B) C2C12 cells with stable knockdown of LRP5 and LRP6
were transiently transfected with the BAT-luc transcriptional reporter
construct and stimulated with control (pcDNA CM) or Wnt3a
conditioned media (Wnt3a CM). Luciferase activity was determined
16 h after stimulation. (C) C2C12 cells with stable knockdown of LRP5
and LRP6 were stimulated with the indicated conditioned media. After
16 h of stimulation RNA was isolated and AXIN2 mRNA levels were
determined by qRT-PCR.
doi:10.1371/journal.pone.0062295.g001
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LRP6 by shRNA or siRNA (data not shown and [33]). When
using another activator of canonical Wnt signaling (recombinant
Wnt9b) there was a weak induction of AXIN2 mRNA expression.
Whereas this response was strongly inhibited by LRP5 knock-
down, it was only moderately inhibited by LRP6 depletion (Fig.
S1b).
Sclerostin Inhibits Wnt-induced Osteoblast
Differentiation, but not LRP5 and LRP6 Phosphorylation
Consistent with previous reports [10,16,17], we found that
Sclerostin-containing conditioned media (Sclerostin-CM; SCL-
CM) inhibited Wnt-induced BAT-luc transcriptional reporter
activation (Fig. 2a) and Wnt3a-induced AXIN2 mRNA transcrip-
tion (Fig. 2b) in the osteoprogenitor cell line KS483. Wnt-induced
Alkaline Phosphatase (ALP) activity, an early marker for osteoblast
differentiation, was also inhibited by Sclerostin-CM (Fig. 2c).
Similar results were obtained using recombinant murine Sclerostin
instead of Sclerostin-CM (data not shown).
After stimulation with Wnt3a, LRP6 is phosphorylated, which
results in stabilization of b-Catenin [34]. In contrast to the classical
Wnt antagonist DKK1, Sclerostin did not inhibit Wnt3a-induced
phosphorylation of LRP6 on serine 1490 in the first PPSPXS motif
(Fig. 2d and 2e). Similar results were obtained for Wnt3a-induced
LRP5 phosphorylation (data no shown), suggesting that Sclerostin
acts downstream of LRP5/6. To activate Wnt signaling responses
without activating LRP5/6 we used ectopic expression of
Dishevelled 1 (DVL1), Dishevelled 2 (DVL2), Dishevelled 3
(DVL3) and a degradation insensitive b-Catenin mutant (b-CAT
SA). When over-expressed these proteins activate the BAT-luc
reporter, but none of these activations could be blocked by
Sclerostin (Fig. 2f). Thus, the mechanism of action of LRP5/6
inhibition by Sclerostin appears to be different than by DKK1.
Sclerostin Differentially Interacts with LRP5 and LRP6
To gain more insight into the interaction of Sclerostin with
LRP5 and LRP6, we radiolabelled recombinant murine Sclerostin
using 125Iodine. Sclerostin-interacting cell surface proteins of
different cell lines were affinity-labeled with [125I]Sclerostin, upon
which the formed complexes were crosslinked using Bis(Sulfosuc-
cinimidyl) suberate (BS3) and Disuccinimidyl suberate (DSS).
Subsequently, the complexes containing LRP5 and LRP6 were
immunoprecipitated using LRP5 or LRP6 specific antibodies.
Specificity of these anti-LRP5 and anti-LRP6 antibodies was
tested in COS-1 cells over-expressing tagged LRP5 and LRP6; no
cross-reactivity was observed (Fig. S2a). Samples were separated
by SDS-PAGE and the radioactive signal was visualized using
a phosphorimager screen. Sclerostin was found to bind strongly to
LRP6 and weakly to LRP5 (Fig. 3a). The expression of LRP5 and
LRP6 was measured by Western blot and qRT-PCR. The mRNA
expression levels were similar to the protein expression with
apparent higher levels of LRP5 and -6 transcription in C3H10T1/
2 cells than in other examined cell types (Fig. 3b, S2b and S2c). In
all the examined cell types recombinant Wnt3a induced AXIN2
mRNA expression, and Sclerostin attenuated this expression. No
apparent relation could be observed between the expression of
LRP5 or LRP6 and the level of inhibition (Fig. S2d). In the
crosslinking experiments a very strong band was observed with an
apparent size of approximately 50 kDa (Fig. 3a, asterisks), which
was not immunoprecipitated using LRP5 or LRP6 specific
antibodies. This suggests a Sclerostin binding partner with
a molecular weight of around 25 kDa which is not in complex
with LRP5/6, and may actually be Sclerostin itself. Sclerostin is
a monomer in solution even at rather elevated concentrations [35],
but may transiently form dimers under the conditions of the
crosslinking procedure.
Using lentiviral shRNAs we created KS483 cell lines with LRP5
or LRP6 knockdown. Knockdown was confirmed by Western
blotting (Fig. 3c). These KS483 knockdown lines were affinity
labeled with [125I]Sclerostin, complexes were crosslinked and
those containing LRP5 and LRP6 were immunoprecipitated. With
the use of ImageQuant TL software (Amersham Biosciences) we
quantified the radioactive signal. Whereas knockdown of LRP6
resulted in a strong reduction on the total binding of [125I]Scler-
ostin to the high molecular weight complexes (containing both
LRP5 and LRP6), knockdown of LRP5 had little to no effect,
consistent with LRP6 being the main interaction partner of
Sclerostin in KS483 cells. In addition, knockdown of either LRP5
or LRP6 had no effect on binding of Sclerostin to the remaining
LRP (Fig. 3d and 3e).
Internalization of Sclerostin-GFP
Based upon previous reports on the mechanism of action of
DKK1 [36], we hypothesized that Sclerostin is internalized in
a LRP5/6 dependent manner similar to DKK1. With LRP6 being
the main receptor for Sclerostin, we stably transfected 293 cells
with a plasmid encoding LRP6-V5 in order to study the binding
and internalization of recombinant murine Sclerostin-GFP. LRP6
over-expressing cells were incubated on ice (to prevent in-
ternalization) with Sclerostin-GFP fusion protein or GFP as
a negative control, after incubation for 1.5 h to allow for binding
the cells were placed in a 37uC incubator for 30 min. Cells over-
expressing LRP6 showed an increase of Sclerostin-GFP binding
and internalization compared to control cells transfected with
empty vector (Fig. 4a). Internalized Sclerostin-GFP was present as
small puncta. When incubated for longer time at 37uC the
Sclerostin-GFP protein was degraded in a proteasome-dependent
manner, as degradation could be prevented by adding the
proteasomal inhibitor MG132 (Fig. 4b). As expected, binding
and internalization of Sclerostin-GFP could be competed away
with an excess of non-tagged recombinant murine Sclerostin
(Fig. 4c). Wild type Sclerostin was a highly effective competitor of
Sclerostin-GFP binding to LRP6. The GFP-tag on Sclerostin may
attenuate its apparent affinity for LRP6.
To investigate which kind of endocytosis route is employed by
Sclerostin-GFP/LRP6 we used two inhibitors: Monodansylcada-
verine for inhibition of the Clathrin-dependent endocytosis pathway [37] and
Nystatin to inhibit the Caveolin-dependent endocytosis pathway
[38]. Both inhibitors showed no effect on the binding of Sclerostin-
GFP to LRP6 over-expressing cells. With respect to internaliza-
tion, Monodansylcadaverine clearly showed inhibition of in-
ternalization, whereas Nystatin had no effect on internalization
(Fig. 4d). Thus, these results suggest that Sclerostin-GFP is
internalized via the Clathrin-mediated endocytosis pathway,
similar as GFP-DKK1 ([36], and data not shown).
Binding and internalization of Sclerostin-GFP possibly to
endogenous LRPs was also observed in KS483, albeit weaker
than in LRP6 over-expressing cells (Fig. S2e). In these cells,
knockdown of LRP5 or LRP6 had no apparent effect on binding
and internalization of Sclerostin-GFP (Fig. S2f), suggesting that
Sclerostin-GFP may also be internalized in a LRP5/6 independent
manner in KS483 cells.
Inhibition of Sclerostin Function by Neutralizing
Antibodies
Antibodies against Sclerostin were generated from the HuCAL
GOLD antibody library [39] using recombinant murine Sclerostin
in a solution panning (T.D. Mueller et al., manuscript in
Sclerostin and Wnt/LRP6 Signaling
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Figure 2. Sclerostin inhibits Wnt3a-induced osteoblast differentiation, but not LRP5/6 phosphorylation. (A) KS483 cells were transiently
transfected with the BAT-luc reporter construct. The cells were stimulated with conditioned control media (pcDNA CM) or Wnt3a conditioned media
(Wnt3a CM), in the presence of Sclerostin conditioned media (SCL CM) or Dickkopf 1 conditioned media (DKK1 CM). Luciferase activity was
determined 16 h after stimulation. (B) KS483 cells were stimulated with the indicated conditioned media and after 16 h RNA was isolated and AXIN2
mRNA levels were determined by qRT-PCR. (C) KS483 cells were stimulated with the indicated conditioned media and after three days the cells were
fixed and stained for ALP activity. Staining was dissolved and measured spectrophotometrically. (D) KS483 cells were stimulated with the indicated
conditioned media, next the cells were lysed and Western blot was performed. (E) Phospho-LRP5/6 bands were quantified and normalised to the
Sclerostin and Wnt/LRP6 Signaling
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LRP6 bands. (F) KS483 cells were transiently transfected with the BAT-luc reporter construct together with the indicated plasmids (Dvl1, Dvl2, Dvl3 or
bCAT-SA). The cells were stimulated with conditioned control media or Sclerostin conditioned media. Luciferase activity was determined 16 h after
stimulation.
doi:10.1371/journal.pone.0062295.g002
Figure 3. Sclerostin differentially interacts with LRP5/6. (A) C2C12, C3H10T1/2, ATDC5 and KS483 were affinity labeled using [125I]Sclerostin,
followed by chemical crosslinking. Cells were lysed and an immunoprecipitation was performed using LRP5 and LRP6 antibodies. Samples were
separated on a SDS-PAGE gel and the radioactive signal was visualized using a phosphorimager screen. The unknown 50 kD band is marked with an
asteriks on the short exposure of the KS483 input. (B) C2C12, C3H10T1/2, ATDC5 and KS483 cells were lysed and Western blot was performed to
determine the expression of LRP5 and LRP6, GAPDH was used as a loading control. (C) Lysates were made of KS483 control cells (pLKO and NT-
shRNA) and KS483 cells with stable LRP5 or LRP6 knockdown. Knockdown efficiency was determined by Western blotting. (D) KS483 control cells and
KS483 cells with stable LRP5 or LRP6 knockdown were affinity labeled using [125I]Sclerostin, followed by chemical crosslinking. Cells were lysed and an
immunoprecipitation was performed using LRP5 and LRP6 antibodies. LRP5 and LRP6 antibodies do not cross-react (Fig. S1a). Samples were
separated on a SDS-PAGE gel and the radioactive signal was visualized using a phosphorimager screen. (E) High molecular weight bands
corresponding to LRP5 and LRP6 were quantified using ImageQuant TL v2003.03 software (Amersham Biosciences), and normalized to the pLKO
control.
doi:10.1371/journal.pone.0062295.g003
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preparation). The Fab antibodies showing the best binding to
Sclerostin were tested to see if they had an effect on binding of
Sclerostin-GFP to 293 cells over-expressing LRP6. A single Fab
antibody (AbD09097) inhibited binding of Sclerostin-GFP. Two
other Fab antibodies (AbD09101 and AbD09172) although able to
bind Sclerostin, were not able to neutralize the binding of
Sclerostin-GFP to LRP6 (Fig. 5a and data not shown). A full
human/mouse chimeric IgG2a antibody was created by cloning
the binding epitopes of AbD09097 (VH and VL segments) into the
pMORPH2_h/mIg vector [40]. KS483 cells were affinity labeled
with [125I]Sclerostin that was pre-incubated for 30 minutes at
room temperature with controls (Fc and aGFP-IgG) or Sclerostin
neutralizing antibodies (AbD09097 and aSCL-IgG), followed by
chemical crosslinking. Pre-incubation of [125I]Sclerostin with the
neutralizing antibodies blocked the binding to LRP5/6 (Fig. 5b).
This antibody was also used in a BAT-luc reporter assay in KS483
cells, with a human/mouse chimeric IgG2a antibody against GFP
serving as a control. In the BAT-luc reporter assay the anti-
Sclerostin antibody showed a significant rescue of the inhibition by
Sclerostin on the Wnt3a induced BAT-luc activity (Fig. 5c).
Furthermore this anti-Sclerostin antibody was also able to rescue
the inhibition by Sclerostin on Wnt3a-induced AXIN2 mRNA
expression (Fig. 5d) as well as Sclerostin-mediated inhibition of
Alkaline Phosphatase (ALP) activity induced by Wnt3a (Fig. 5e).
To minimize effects of Wnt3a on proliferation, KS483 cells were
stimulated with Wnt3a after they had reached confluency, a state
in which KS483 cells are contact inhibited in growth. Quantifi-
cation of the Alkaline Phosphatase activity showed a significant
rescue of around 50% (Fig. 5f). Thus AbD09097 has a potent
neutralizing effect on Sclerostin-mediated inhibition of Wnt-
induced signaling in osteoprogenitor cells.
Figure 4. Internalization of Sclerostin-GFP. (A) 293 cells stably over-expressing LRP6 (293-LRP6) or containing an empty pcDNA3 vector, were
incubated with GFP or Sclerostin-GFP for 1.5 hours at 4uC. After binding the cells were transferred to a 37uC incubator for 30 minutes, after this
incubation the cells were fixed and confocal images were taken. (B) 293-LRP6 cells were first pre-treated with DMSO or MG132 (10 mM) for 4 hours,
and then incubated with Sclerostin-GFP for 1.5 h at 4uC. After binding the cells were transferred to a 37uC incubator for the indicated time periods,
next the cells were fixed and confocal images were taken. (C) 293-LRP6 cells were incubated with Sclerostin-GFP with different amounts of non-
tagged Sclerostin for 1.5 h at 4uC. After binding the cells were transferred to a 37uC incubator for 30 minutes, after this incubation the cells were fixed
and confocal images were taken. (D) 293-LRP6 cells were pre-treated with Monodansylcadaverine (200 mM) or Nystatin (25 mg/ml) or its relevant
controls for 30 minutes. Next Sclerostin-GFP was added and the cells were incubated for 1.5 h at 4uC. After binding the cells were transferred to a 37uC
incubator for 30 minutes, next the cells were fixed and confocal images were taken.
doi:10.1371/journal.pone.0062295.g004
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Figure 5. Inhibition of Sclerostin function by antibodies. (A) Sclerostin-GFP was pre-incubated with Fc or the different Fabs raised against
Sclerostin for 30 minutes at room temperature, next the mixtures were added to 293-LRP6 cells for 1.5h at 4uC. After binding the cells were
transferred to a 37uC incubator for 30 minutes, next the cells were fixed and confocal images were taken. (B) KS483 cells were affinity labeled with
[125I]Sclerostin that was pre-incubated for 30 minutes at room temperature with controls (Fc and aGFP-IgG) or Sclerostin neutralizing antibodies
(AbD9097 and aSCL-IgG), followed by chemical crosslinking. Cells were lysed and samples were separated by SDS-PAGE. The radioactive signal was
Sclerostin and Wnt/LRP6 Signaling
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Discussion
During adulthood bone remodeling performs a pivotal role in
maintaining bone mass and integrity. When the balance between
bone forming osteoblasts and bone resorbing osteoclasts goes
awry, this may lead to metabolic bone diseases that are
characterized by either too low or high bone mass. Sclerosteosis
is a rare high bone mass disorder that is caused by loss of Sclerostin
expression [9,10]. Sclerostin, which is expressed by osteocytes, is
a negative regulator of canonical Wnt signaling. Here we show
that canonical Wnt-induced responses in mesenchymal cells are
critically dependent on LRP5 and LRP6. Sclerostin preferentially
binds to LRP6, and to a significantly lesser extent to LRP5, and
inhibits canonical Wnt-induced responses. In addition, we show
that GFP-tagged Sclerostin is internalized, and subsequently
degraded in a proteasome-dependent manner. Moreover, we
describe a recombinant antibody selected by phage display that
specifically interferes with binding of Sclerostin to the Wnt co-
receptors LRP5 and LRP6 and stimulates osteoblast differentia-
tion. Such antibodies may in the future be used for anabolic
therapy of bone-related disorders as has been described for other
Sclerostin antibodies [41–46].
Consistent with previous reports [16] we found that Sclerostin
attenuated Wnt3a-induced responses, but full inhibition was never
achieved. This observation might be explained with the preferen-
tial binding of Sclerostin to LRP6. Both receptors, LRP5 and 6,
appear to mediate Wnt-induced responses as knockdown of only
either one of both LRPs is insufficient to block Wnt signaling
completely. In the presence of Sclerostin, Wnt/LRP6 signaling
might be preferentially impaired, while LRP5-mediated signaling
might be maintained, since knockdown of LRP6 did not lead to
enhanced binding of Sclerostin to LRP5.
Compared to Sclerostin, DKK1 was found to be more potent in
inhibiting Wnt3a-induced responses. DKK1 is known to inhibit
both Wnt/LRP5 and Wnt/LRP6 responses [31,32,47]. Consistent
with previous reports, we find that DKK1 inhibits LRP6
phosphorylation by Glycogen synthase kinase-3 (GSK-3) and
Casein kinase 1 gamma (CK1c) [48]. However, Sclerostin appears
not to exert the same effect. This indicates that the mechanism of
action of DKK1 and Sclerostin to inhibit Wnt3a activity is
different despite the fact that both Wnt inhibitors target the same
Wnt receptor component. This is fully in line with the differential
binding domains of both antagonists for LRP5/6 [49–51].
Whereas Sclerostin interacts with the first propeller region,
DKK1 interacts with the third and fourth propellers [50,51].
Also, Sclerostin and DKK1 have differential modulatory and
context dependent effects on different Wnt ligands. Sclerostin has
been reported to potentiate Wnt reporter activity [21], however
we have not observed this. This could be due to specific assay
conditions, e.g. transfection versus exogenous addition of proteins,
or reflecting different expression patterns of the components of the
signaling complex. Since different Wnt family members have been
shown to bind different domains of LRP5/6 [18,21,30,52]. The
internalization of Sclerostin-GFP in a Monodansylcadaverine-
sensitive manner suggests that Sclerostin is internalized via
a Clathrin-dependent route. DKK1 was previously shown to
induce the internalization and recycling of LRP6 via a Clathrin-
dependent mechanism [28,36]. Internalized DKK1 was degraded
and this could be inhibited by lysosome inhibitors [48]. We found
that ectopic expression of LRP6 in 293T cells greatly enhanced
Sclerostin-GFP binding and internalization. This suggests that
Sclerostin’s high affinity receptor LRP6 mediates the internaliza-
tion under these conditions. However, in non-transfected KS483 cells
shRNA-mediated knockdown of LRP5/6 did not significantly affect
the binding and internalization of Sclerostin-GFP, suggesting that
Sclerostin-GFP may also be internalized in a LRP5/6 independent
manner.
Similar as reported for the anti-Sclerostin antibody described by
Veverka et al. [53], we found that our anti-Sclerostin antibody
rescued the inhibitory effect of Sclerostin on Wnt3a-induced
reporter activity. We extended the analysis and demonstrated that
this anti-Sclerostin antibody antagonized Sclerostin-mediated
inhibition on Wnt-induced AXIN2 expression and Wnt-3a-
induced ALP activity. Moreover, we found that our Sclerostin-
neutralizing antibody inhibited Sclerostin-GFP binding to cell
surface associated LRP6 and its subsequent internalization and
degradation.
So far, antibodies that have been shown to interfere with
Sclerostin-mediated inhibition of canonical Wnt signaling have
been shown to interact with loop 2 of sclerostin [53]. Structural
studies analyzing the N-terminal propeller domain of LRP6 indeed
revealed a binding site for a key sequence motif NXI present not
only in Sclerostin (amino acid sequence NAI) but also in the
members of the DKK family (DKK1: NAI; DKK2: NSI; DKK3:
NNI) that is potentially involved in the specific recognition and
binding of these Wnt inhibitors to the co-receptor LRP6 [51].
However, despite this potential overlapping binding site for
Sclerostin and DKK family members [16,51], our data strongly
suggest that the Wnt3a inhibition mechanism by Sclerostin and
DKKs differ on the extra- as well as on the intracellular site
thereby likely disqualifying a simple competition of Wnt and Wnt
inhibitors for a shared binding epitope on LRP5/6.
Materials and Methods
Antibodies
Anti-LRP5 (C-20) was purchased from Santa-Cruz, anti-LRP6
(1C10) from Abcam, phospho-LRP5/6 from Cell Signaling, anti-
GAPDH (6C5) from Millipore and anti- FLAG-M2 from Sigma.
Recombinant Wnts
Recombinant Wnt3a and Wnt9b were purchased from R&D
systems.
Recombinant Sclerostin Proteins
Recombinant full-length murine Sclerostin derived from
expression in Baculovirus-transfected insect cells was prepared as
described previously [35]. A Sclerostin-GFP fusion protein was
obtained by inserting the cDNA encoding for eGFP at the C-
terminal end of the above described expression construct for
visualized using a phosphorimager screen. (C) KS483 cells were transiently transfected with the BAT-luc reporter construct. The cells were stimulated
with conditioned control media (pcDNA CM) or Wnt3a conditioned media (Wnt3a CM), together or without Sclerostin conditioned (SCL CM) media
that was pre-incubated with either anti GFP-IgG2a (aGFP-IgG) or anti Sclerostin-IgG2a (aSCL-IgG) for 30 minutes at room temperature. (D) KS483 cells
were stimulated with control conditioned media or Wnt3a conditioned media (Wnt3a CM), together or without Sclerostin conditioned media that
was pre-incubated with either anti GFP-IgG2a (aGFP-IgG) or anti Sclerostin-IgG2a (aSCL-IgG) for 30 minutes at room temperature. RNA was isolated
and AXIN2 mRNA levels were determined by qRT-PCR. (E) KS483 cells were stimulated with the indicated conditioned media, which were pre-
incubated with the indicated Fab antibodies. Three days after stimulation cells were fixed and stained for alkaline phosphatase activity. Results were
quantified using spectrometry (F).
doi:10.1371/journal.pone.0062295.g005
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murine Sclerostin. As only an XhoI restriction site was available for
the insertion of the GFP cDNA sequence, the expression vector
pMKI_mSOST was modified by mutating the stop codon at the
39 end of the Sclerostin cDNA to encode a glycine residue ahead
of the XhoI restriction site. The cDNA of eGFP was then amplified
from the bacterial expression vector pET28b_eGFP by PCR
including a 59 extension for an XhoI and an EcoRI restriction site
and a 39 extension encoding a stop codon, a XhoI and a ScaI
restriction site. By analytical restriction analysis using a combina-
tion of BamHI and EcoRI or BamHI and ScaI the orientation of the
GFP gene with respect to the Sclerostin cDNA was tested and the
correctness of the cDNA sequence of the Sclerostin-GFP fusion
was verified by DNA sequencing. Recombinant Baculovirus was
obtained from cotransfection of the transfer vector pMKI_m-
SOST-GFP and linearized virus DNA (BAC-3000 virus kit,
Novagen) into Sf9 insect cells. By using recombinant BAC-3000
virus production the yield of Sclerostin could be increased.
Compared to BAC-2000 virus DNA, BAC-3000 DNA lacks the
secreted Baculovirus genes chiA and v-cath, which encode for two
secreted enzymes, a chitinase and a Cathepsin protease, both of
which can lower the yield of recombinant protein. Virus selection
and amplification was performed as suggested by the manufac-
turer. For protein production, semi-adherent growing TriEX
insect cells (Novagen) were transfected with recombinant virus
using a MOI of 5. Cell supernatant was harvested 96 h post
transfection and clarified by centrifugation. After dialysis against
50 mM sodium phosphate pH 8.3, 300 mM NaCl, 10 mM
Imidazole Sclerostin-GFP fusion protein was isolated by metal
affinity chromatography using a Ni-NTA Perfect Pro column (5
Prime) and eluting the protein with dialysis buffer containing
250 mM Imidazole. Protein-containing fractions were pooled and
dialyzed against 10 mM HEPES pH 7 u.4, 3.4 mM EDTA,
150 mM NaCl. For final purification a cation exchange chroma-
tography was performed employing a CM-Sepharose HiTrap
column (GE healthcare) and a linear gradient from 150 mM to
1 M NaCl in 10 mM HEPES pH 7.4. Fractions were analyzed by
SDS-PAGE and pooled accordingly. Sclerostin-GFP was finally
dialyzed against PBS, two times diluted with 86% Glycerol for
cryoprotection and stored at 220uC until further use.
GFP protein for control studies was obtained from bacterial
expression using the expression vector pET28b_eGFP encoding
eGFP with an N-terminal His6-tag and a subsequent thrombin
cleavage site. Isolation and purification of recombinant GFP via
metal affinity and a subsequent cation exchange chromatography
followed the protocol described above.
Cell Culture
COS, 293 and C2C12 (ATCC) cells were cultured in
Dulbecco’s modified Eagle’s medium with high glucose (GIBCO)
containing 10% FBS (GIBCO). C3H10T1/2 (ATCC) and KS483
[54] cells were cultured in aMEM (GIBCO) containing 10% FBS.
ATDC5 [55] cells were cultured in DMEM/F12 (GIBCO)
containing 10% FBS (GIBCO). All cells were cultured at at
37uC with 5% CO2.
Transcriptional Reporter Assay
Cells were seeded in 24-well plates and transiently transfected
for 4 hours with the different expression plasmids, a b-Galacto-
sidase expression plasmid and the BAT-luc reporter construct [56]
using Lipofectamine reagent (Invitrogen) according to the
manufacturer’s protocol. After two days the cells were serum-
starved for 8 hours and subsequently stimulated for 16 hours with
the indicated conditioned medium. Cells were washed, lysed and
activity of Luciferase and b-Galactosidase, which served as
a control to correct for transfection efficiency, was determined.
Each transfection was carried out in triplicate and representative
experiments are shown.
RNA Isolation and Quantitative Real-time PCR
Total RNA was isolated using the Nucleospin RNA II kit
(Macherery-Nagel) according to the manufacturer’s instructions.
RT-PCR was performed using the RevertAid H Minus First
Strand cDNA synthesis kit (Fermentas) following the manufac-
turer’s recommendation. Expression of mouse LRP5, LRP6,
AXIN2 and GAPDH was analyzed in triplicate. PCRs were
performed using SYBR GREEN (Roche) on the StepOne Plus
real-time PCR system (Applied Biosystems). Gene transcription
levels were determined with the comparative DCt method using
GAPDH as a reference. PCR primers; mouse LRP5 forward
59TGG GAC TCA AAG CCG TGA AT39, mouse LRP5 reverse
59TGG CTG CAC CCT CCA TTT39, mouse LRP6 forward
59AGA TCC ATC AAG TGG GTT CAT GTA39, mouse LRP6
reverse 59AAG CGA CTT GAG CCA TCC AT39, mouse
AXIN2 forward 59GGT TCC GGC TAT GTC TTT GC39,
mouse AXIN2 reverse 59CAG TGC GTC GCT GGA TAA
CTC3, mouse GAPDH forward 59AAC TTT GGC ATT GTG
GAA GG39, mouse GAPDH reverse 59ACA CAT TGG GGG
TAG GAA CA39.
Western Blot Analysis
Cells were seeded in 6-well plates and allowed to grow to
confluence. Cells were washed with PBS and lysed in SDS sample
buffer. Samples were boiled for 5 minutes and subjected to SDS-
PAGE and Western blotting.
[125I]Sclerostin Binding Assay
Iodination of recombinant murine full-length Sclerostin was
performed according to the chloramine T method and cells were
subsequently affinity-labeled with the radioactive ligand as de-
scribed before [57,58]. In brief, cells were incubated on ice for 3
hours with the radioactive ligand. After incubation, cells were
washed and crosslinking was performed using 0.27 mM Disucci-
nimidyl suberate (DSS, Pierce) and 0.09 mM Bis(sulfosuccinimi-
dyl)suberate (BS3, Pierce) for 15 minutes. Cells were washed,
scraped and lysed. Lysates were incubated with the respective
antisera for 2.5 hours and immune complexes were precipitated by
adding protein A Sepharose (Amersham Biosciences). Samples
were washed, boiled in SDS sample buffer and subjected to SDS-
PAGE. Gels were dried and scanned with the STORM imaging
system (Amersham Biosciences). Bands were quantified using
ImageQuant TL v2003.03 software (Amersham Biosciences).
Sclerostin-GFP Internalization Assay
Cells were grown on glass slides. Cells were cooled down on ice
for 0.5 h and subsequently incubated for 2.5 h on ice with
500 ng/ml Sclerostin-GFP. Next the cells were placed in a 37uC
incubator for the indicated time. After washing one time with PBS
the cells were fixed with 3% paraformaldehyde in phosphate-
buffer. Slides were mounted and confocal microscopy pictures
were taken (Leica TCS SL).
Statistical Analysis
The unpaired two-tailed Student’s t test was used to determine
the significance of differences between means. All relevant
comparisons were significantly different (P,0.05), unless otherwise
indicated. Experiments were performed at least three times and
representative results are shown.
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